Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients

Clinica Chimica Acta

Volumn 430, Issue , 2014, Pages 63-70

  Wang, Shuai ^a   Han, Xiaohong ^a   Hu, Xingsheng ^a   Wang, Xiaoyuan ^a   Zhao, Lingdi ^a   Tang, Le ^a   Feng, Yun ^a   Wu, Di ^a   Sun, Yan ^a   Shi, Yuankai ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Biomarker; EGFR; Lung cancer; Plasma

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; ICOTINIB; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CANCER TISSUE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; EGFR GENE; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MUTATION; PERSONALIZED MEDICINE; PROGNOSIS; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 84892880094     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.12.026     Document Type: Article

References (26)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Ramalingam S.S., Owonikoko T.K., Khuri F.R. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 2011, 61:91-112.
3. Shi Y., Zhang L., Liu X., et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013, 14:953-961.
4. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
5. Mack P.C., Holland W.S., Burich R.A., et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol 2009, 4:1466-1472.
6. Kimura H., Suminoe M., Kasahara K., et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 2007, 97:778-784.
7. Normanno N., Bianco C., Strizzi L., et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005, 6:243-257.
8. Iyer S., Wang Z.G., Akhtari M., et al. Targeting TGF-β signaling for cancer therapy. Cancer Biol Ther 2005, 4:261-266.
9. Zhao X., Han R.B., Zhao J., et al. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration 2013, 85:119-125.
10. Kimura H., Kasahara K., Shibata K., et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol 2006, 1:260-267.
11. Yung T.K., Chan K.C., Mok T.S., et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in nonsmall cell lung cancer patients. Clin Cancer Res 2009, 15:2076-2084.
12. Bai H., Mao L., Wang H.S., et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non small-cell lung cancer. J Clin Oncol 2009, 27:2653-2659.
13. Goto K., Ichinose Y., Ohe Y., et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib orcarboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012, 7:115-121.
14. Kuang Y., Rogers A., Yeap B.Y., et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009, 15:2630-2636.
15. Brevet M., Johnson M.L., Azzoli C.G., et al. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 2011, 73:96-102.
16. Jahr S., Hentze H., Englisch S., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665.
17. Brevet M., Johnson M.L., Azzoli C.G., et al. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 2011, 73:96-102.
18. Zhao L., Sheldon K., Chen M., et al. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer 2008 Feb, 59:232-239.
19. Zhao L., Ji W., Zhang L., et al. Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:521-525.
20. Kumar S., Guleria R., Mohan A., et al. Utility of plasma tumour necrosis factor-alpha and transforming growth factor-beta1 as predictors of survival and treatment outcome in advanced non-small cell lung carcinoma. Biomarkers 2010, 15:446-453.
21. Addison C.L., Ding K., Zhao H., et al. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol 2010, 28:5247-5256.
22. Ishikawa N., Daigo Y., Takano A., et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005, 65:9176-9184.
23. Masago K., Fujita S., Hatachi Y., et al. Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. Cancer Sci 2008, 99:2295-2301.
24. Sozzi G., Conte D., Mariani L., et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001, 61:4675-4678.
25. Paci M., Maramotti S., Bellesia E., et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 2009, 64:92-97.
26. Ludovini V., Pistola L., Gregorc V., et al. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the Perugia multidisciplinary team for thoraciconcology. J Thorac Oncol 2008, 3:365-373.